About the Authors
- Heike J. Wobst
-
Contributed equally to this work with: Heike J. Wobst, Louise Delsing
Affiliation AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America
- Louise Delsing
-
Contributed equally to this work with: Heike J. Wobst, Louise Delsing
Affiliations AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America, AstraZeneca, Discovery Science, Innovative Medicines and Early Development Biotech Unit, Mölndal, Sweden
- Nicholas J. Brandon
-
Affiliations AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America, AstraZeneca, Neuroscience, Innovative Medicines and Early Development, Waltham, MA, United States of America
- Stephen J. Moss
-
* E-mail: Stephen.Moss@Tufts.edu
Affiliations AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America, Department of Neuroscience, Tufts University School of Medicine, Boston, MA, United States of America
Competing Interests
SJM serves as a consultant for AstraZeneca and SAGE Therapeutics in relationships that are regulated by Tufts University and do not impact on this study. NJB is a full-time employee and shareholder in AstraZeneca. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: HJW NJB SJM. Formal analysis: HJW LD. Investigation: HJW LD. Methodology: HJW. Supervision: HJW NJB SJM. Validation: HJW LD. Visualization: HJW LD. Writing – original draft: HJW. Writing – review & editing: HJW LD NJB SJM.